BIAF
NASD bioAffinity Technologies, Inc.$6.06 ↑ +0.00 (+0.00%) Trading Up from the previous close of $6.06, $0.18 below the day’s high of $6.24
- YTD change
- +413.14%
- vs 20-day SMA
- -28.59%
- vs 200-day SMA
- +152.49%
Price ranges
Price & Performance
+1.88 (+44.86%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 98.7% away from all-time highs of $466.50
- BIAF is up 413% since the beginning of the year
- BIAF is up 118% over the past 12 months
- BIAF is down 38% over the past 1 month
- 6% of all BIAF investors are betting against BIAF
BIAF reads poor: price sits above one of the two key moving averages, the 12-month move is +132.0%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -22.67%
- vs 8-day SMA
- -18.24%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.